For Healthcare Professionals

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

clipboard-pencil

About the study

This is a non-interventional, multinational, multi-centre study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in patients treated with osilodrostat for endogenous Cushing's Syndrome
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Written informed consent obtained prior to registration of any patient data
  2. Male or female patients aged 18 years or older with endogenous CS treated with osilodrostat. Treatment with osilodrostat can either be initiated at the first visit of the study or can have been initiated before screening.

EXCLUSION CRITERIA

Exclusion Criteria:

  1. Patients with exogenous CS
  2. Patients with Pseudo CS
  3. Patients participating in an interventional clinical trial with an investigational drug.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall +41 79 440 58 97Email iconEmail Study Center

Study’s details


Contition

Endogenous Cushing's Syndrome

Age (in years)

18+

Participants needed

100

Est. Completion Date

Feb 28, 2029

Treatment type

Observational


Sponsor

RECORDATI GROUP

ClinicalTrials.gov identifier

NCT05382156

Study number

LCI699-RECAG-PASS-0572

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.